Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027819 (neuroblastoma)
 27,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Adrenal cortical carcinoma in a 4 1/4-month-old girl was treated by surgery in combination with actinomycin D, cyclophosphamide, and 5-fluorouracil given daily for 5 days every third week for 13 1/2 months. Postoperative hypertension and raised 24-hour 17-hydroxy- and 21-oxosteroids suggested residual microscopical tumour activity. These findings resolved during chemotherapy. The patient is alive and well 22 months after completing chemotherapy. Adrenal cortical carcinoma may rarely mimic neuroblastoma or nephroblastoma when the tumour is not clinically secretory.
 ...
PMID:Unusual case of adrenal cortical carcinoma in a female infant. 64 50

The effects of high concentrations of CO2 on experimental murine neuroblastoma tumor were studied. Similar to the experience with the animal model of Wilms' tumor, the local growth of this neuroblastoma model was not affected by concentrations of 76% and 55% of CO2 applied for 10 and 30 minutes. The tumor bearing animals exposed to different CO2 concentrations tended to develop metastases more frequently than the control groups, although no change in survival was noted. Different animals and additional tumor models could be used by others to study the effects of different CO2 concentrations at different exposure times.
 ...
PMID:A study of the effect of CO2 on experimental neuroblastoma. 67 22

In order to determine the proportion of congenital neoplasias, a study of 1 076 malignant neoplasias was carried out at the Pathology Department of the Hospital Infantil de Mexico. As unquestionably congenital malignant neoplasias were considered those detected since birth and as possibly congenital, those identified during the first year of life of the patient. As a whole, in this series of neoplasias, approximately one case was found of the sum of the congenital group and the possibly congenital, to 4.5 of the total series. However the proportion of the group of congenital malignant neoplasias and that of possibly congenital varied for each type of neoplasias in particular. Excluding malignant neoplasias of hematopoietic tissues, retinoblastoma, nephroblastoma and neuroblastoma were the malignant neoplasias most frequently found.
 ...
PMID:[Congenital malignant neoplasms]. 75 92

32 children with different types of tumors have bben treated with peptichemio. The efficacy was excellent in rhabdomyosarcoma and embrional sarcoma; encouraging in neuroblastoma, Wilms tumor and histiocytosis X. Side and toxic effects were minimal. In conclusion we can say that peptichemio is effective in oncologic diseases, but a larger number of patients is required in order to have a better knowledge about the antitumor activity of this drug.
 ...
PMID:Peptichemio in children with neoplastic disease. 79 81

Combination chemotherapy with adriamycin and DTIC was used in 102 evaluable patients under 15 years of age who had previously treated metastatic solid tumors. Responses, defined as 50% or more reduction in all tumor masses, occurred in 10 out of 27 patients with neuroblastoma, 3 out of 8 patients with Wilms tumor, 7 out 15 patients with Ewing sarcoma, 2 out of 6 patients with osteosarcoma, 5 out of 13 patients with rhabdomyosarcoma, and 15 out of 33 patients with miscellaneous tumors which included a patient who had a complete regression of an extensive juvenile angiofibroma. Response rate to combination chemotherapy with adriamycin and DTIC in patients with Ewing sarcoma was significantly superior to the response rate obtained with adriamycin alone in another Southwest Oncology Group Study. Major toxicity included nausea, vomiting, myelosuppression, high incidence of pneumocystis carinii pneumonia (5 patients) and congestive heart failure (4 patients). There was 7 drug-associated deaths due to sepsis (1), pneumocystis carinii pneumonia (4), and congestive heart failure (2).
 ...
PMID:Combination chemotherapy with adramycin (NSC-123127) and dimethyl triazeno imidazole carboxamide (DTIC) (NSC-45388) in children with metastatic solid tumors. 95 60

Retroperitoneal teratoma is the third most common primary retroperitoneal neoplasm of childhood ranking behind neuroblastoma and nephroblastoma. Ten per cent of these tumors are malignant. Two cases of benign retroperitoneal teratoma are reported, and the first description of the angiographic appearance of such a tumor is presented.
 ...
PMID:Retroperitoneal teratoma. 99 59

Ninety-eight children with solid tumors resistant to conventional chemotherapy received adriamycin 90 mg/m2, either as a single intravenous injection or in 6 divided doses administered every 6 hours. Of the 88 evaluable children, 6 (7%) achieved a complete response and 26 (29%) achieved a partial response. Tumors which demonstrated significant response rates were: neuroblastoma (9/18), Wilms' tumor (7/13), rhabdomyosarcoma (4/11), and lymphoma (4/8). The toxicities observed with this regimen included: alopecia, leukopenia, thrombocytopenia, nausea, vomiting, stomatitis, febrile episodes, and ST-segment changes.
 ...
PMID:Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study. 119 48

Adriamycin is a new anticancer antibiotic with a wide spectrum of activity against solid tumours. The results obtained with this agent in 159 patients with histologically confirmed advanced metastastic malignancies are reported. Encouraging results were obtained in patients with sarcomas of bone and soft tissue (12/22). Response was also seen in mesothelioma (3/9) and lung cancer (5/15). A variety of other neoplasms was also treated and results obtained in neuroblastoma, testicular tumours, stomach carcinoma, breast cancer and nephroblastoma are reported. Treatment is discussed, with reference to response rates and toxicity. Results in 72 patients with advanced breast cancer, who received adriamycin in combination with other chemotherapeutic agents, are presented. Seventeen patients with primary liver cancer were also treated with adriamycin. To date, this is the only chemotherapeutic agent that appears to significantly improve survival times in patients with this resistant form of cancer. The prophylactic use of adriamycin against osteogenic sarcoma is also discussed.
 ...
PMID:Adriamycin in the treatment of cancer. 125 Dec 78

Growth factor receptors are important determinants of both normal and abnormal cell growth. We have now used degenerate primers designed from conserved tyrosine kinase domains to identify and clone a novel receptor-like molecule (designated Nbtk-1) from a NB41 mouse neuroblastoma cell line. Nbtk-1 is related to the met proto-oncogene family of tyrosine kinase receptors. Transcripts of approximately 2.1 and 2.6 kb have been found in mouse cell lines and one transcript of approximately 3 kb in human cell lines and in a wide range of primary human tumors, such as neuroblastomas, primitive neuroectodermal tumors (PNETs), Wilms' tumors, and melanomas and in the corresponding normal human tissues. These observations suggest that Nbtk-1 may have important roles in normal and tumor cell growth.
 ...
PMID:Identification of a novel tyrosine kinase receptor-like molecule in neuroblastomas. 128 89

The Department of Pediatric Oncology, Kemerovo, has operated as an interregional center since 1976. Cancer morbidity and epidemiology in children in the Kuzbass region have been studied. Complex treatment yielded good results: 2-20-year survival rate is 89.6% for Hodgkin's disease, nephroblastoma--75.4% and neuroblastoma--38.5%. The improvement in the results obtained makes the case for establishing a department for patient rehabilitation. To function properly, the center needs more beds. It must be in a position to carry out organizational and educational activities in catchment areas. The status of the center must be supported by official documents.
 ...
PMID:[The work of the Kemerovo Interregional Department of Pediatric Oncology]. 130 Jul 89


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>